Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Prelude Therapeutics Inc (NQ: PRLD )

6.730 -0.010 (-0.15%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 20, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 30,324
Open 6.740
Bid (Size) 6.630 (1)
Ask (Size) 6.740 (2)
Prev. Close 6.740
Today's Range 6.280 - 6.740
52wk Range 3.870 - 8.900
Shares Outstanding 47,912,869
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
The 7 Worst Stocks to Buy Now
With the market reeling from the banking crisis, even hardened gamblers should avoid these worst stocks to buy now. 
Via InvestorPlace
Prelude Therapeutics Reports Full Year 2022 Financial Results and Provides Corporate Update
From Prelude Therapeutics, Inc.
Via Globe NewsWire

Performance

YTD
+34.06%
+34.06%
1 Month
+20.18%
+20.18%
3 Month
+36.23%
+36.23%
6 Month
-1.75%
-1.75%
1 Year
-8.68%
-8.68%

More News

Read More
Prelude Therapeutics Announces Clinical Trial Collaboration with BeiGene to Evaluate PRT2527 in Combination with Zanubrutinib in Hematologic Cancers
From Prelude Therapeutics, Inc.
Via Globe NewsWire
Prelude Therapeutics To Participate in Barclays Global Healthcare Conference
From Prelude Therapeutics, Inc.
Via Globe NewsWire
Expert Ratings for Prelude Therapeutics
Via Benzinga
Analyst Ratings for Prelude Therapeutics
Via Benzinga
Prelude Therapeutics To Participate in Two Upcoming Healthcare Investor Conferences
From Prelude Therapeutics, Inc.
Via Globe NewsWire
Why Horizon Global Shares Are Trading Higher By Over 340%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Carvana, Crocs And Other Big Losers From Monday
Via Benzinga
Why This Prelude Therapeutics Analyst Disagrees With 2 Others And Downgraded The Stock
Via Benzinga
Prelude Therapeutics Announces Third Quarter 2022 Financial Results and Provides Business Update
From Prelude Therapeutics, Inc.
Via Globe NewsWire
Marten Transport, Silvergate Capital And Some Other Big Stocks Moving Lower On Tuesday
Via Benzinga
Prelude Therapeutics Receives FDA Clearance of IND for PRT3789, a Potent and Selective First-in-Class SMARCA2 Protein Degrader
From Prelude Therapeutics, Inc.
Via Globe NewsWire
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For July 29, 2022
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
Via Benzinga
38 Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
Stocks That Hit 52-Week Lows On Thursday
Via Benzinga
68 Biggest Movers From Yesterday
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For March 15, 2022
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
Stocks That Hit 52-Week Lows On Tuesday
Via Benzinga
67 Biggest Movers From Yesterday
Via Benzinga
12 Health Care Stocks Moving In Monday's Intraday Session
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For February 28, 2022
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.